MORE THAN A WARRIOR.

A woman with trails to explore.

There’s more to you than HR+/HER2- ABC.

With REVTORPYK, you can focus on being you.

Not actual patients.

4.5 times longer progression-free survival

REVTORPYK + fulvestrant + palbociclib may give people more than 4.5x longer without their cancer progressing vs fulvestrant alone.

REVTORPYK + fulvestrant + palbociclib provided a median of 9.3 months without cancer progressing vs 2.0 months with fulvestrant alone—a difference of 7.3 months.

See results with REVTORPYK-based treatment

What is median progression-free survival (PFS)?

PFS measures how long a treatment kept cancer from progressing. Median PFS is the point in time when half of the people in the study had their cancer progress, while the other half had not.

HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor positive; PIK3CA=phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.